Royalty Pharma (RPRX) vs Sanofi (SNY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Royalty Pharma (RPRX) has outperformed Sanofi (SNY) over the past year, gaining 56.1% versus a loss of 17.6%. Over five years, RPRX leads with a +46.4% price change compared with -17.6% for SNY. Sanofi is the larger company by market cap ($96.40 billion vs $32.48 billion), about 3.0 times the size.
On valuation, Sanofi trades at a lower forward P/E (7.4x vs 9.8x for Royalty Pharma). Sanofi offers the higher dividend yield (10.24% vs 1.62%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RPRX | SNY |
|---|---|---|
| Share price | $56.21 | $40.23 |
| Market cap | $32.48B | $96.40B |
| 1-day change | -0.97% | +0.07% |
| YTD return | +45.47% | -16.98% |
| 1-year return | +56.05% | -17.56% |
| 5-year return | +46.42% | -17.65% |
| P/E ratio (TTM) | 29.90 | 21.17 |
| Forward P/E | 9.80 | 7.45 |
| EPS (TTM) | $1.88 | $1.90 |
| Dividend yield | 1.62% | 10.24% |
| Annual dividend | $0.91 | $4.12 |
| Revenue (latest FY) | $2.38B | — |
| Revenue growth (YoY) | +5.06% | — |
| Net income (latest FY) | $770.95M | — |
| Operating margin | 65.58% | — |
| Net margin | 32.42% | — |
| 52-week high | $64.38 | $52.68 |
| 52-week low | $35.23 | $39.18 |
| Distance from 52-week high | -12.69% | -23.63% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +16.31% | +33.26% |
| Average volume | 2.92M | 2.89M |
| Shares outstanding | 445.28M | 2.40B |
| Employees | 100 | 74,846 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Sanofi is about 3.0 times larger than Royalty Pharma by market value ($96.40B vs $32.48B).
- RPRX has outperformed SNY by 73.6 percentage points over the past year.
- Royalty Pharma trades at a higher earnings multiple (29.9x vs 21.2x trailing P/E).
- Sanofi offers a meaningfully higher dividend yield (10.24% vs 1.62%).
About Royalty Pharma
RPRX stock →Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Sanofi
SNY stock →Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Health Care · Biotechnology: Pharmaceutical Preparations · 74,846 employees
RPRX vs SNY FAQ
Which is bigger, Royalty Pharma or Sanofi?
Sanofi (SNY) is larger, with a market capitalization of $96.40B compared with $32.48B for Royalty Pharma (RPRX).
Which stock has performed better over the past year, RPRX or SNY?
RPRX returned +56.05% over the past 12 months, compared with -17.56% for SNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, RPRX or SNY?
SNY has the lower trailing P/E at 21.2, versus 29.9 for RPRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Royalty Pharma or Sanofi?
Sanofi has the higher yield at 10.24%, compared with 1.62% for Royalty Pharma.
Are Royalty Pharma and Sanofi in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.